Summary of the R&D update held earlier today

Medivir held a short presentation this morning for analysts, journalists and institutional
investors. The presentation from this research & development update is available on our
website under the heading IR & Media/Latest Events.

During October 2009, Medivir commenced a thorough portfolio evaluation with the aim of
creating a focused product portfolio for development in conjunction with partners or inhouse.
A further goal has been to identify future project opportunities within Medivir’s major
area of competence; anti-infectives.

Greater focus on infectious diseases
As the current in-house projects reach their optimal development stage for engaging in
partnerships, resources will be released to enable new infectious disease projects to be
commenced.
The project portfolio now consists of nine projects plus Xerclear™. Six of these projects
relate to anti-infectives and six are partnered, of which with Tibotec/Johnson & Johnson
account for three. The remaining projects are owned and will be run in-house by Medivir
until appropriate decision points for partnership are reached.

Xerclear™ launched in Sweden 15 March
Medivir’s cold sore pharmaceutical, Xerclear™, will be launched next week in Sweden as an
Rx pharmaceutical (prescription-only), shortly followed by Finland. Preparations for an OTC
(prescription-free) launch in Denmark and Sweden are underway and will be carried out
either in conjunction with a European partner or within the Medivir organisation.
Negotiations are underway with potential partners for the European markets, with the goal
of designating a partner during Q2. Meda AB is Medivir’s partner for the product in the USA.

For additional information, please contact
Rein Piir, CFO and VP Investor Relations, Medivir, Tel: +46 (0) 708-537 292.
For more information on Medivir, please see the company website;
www.medivir.se